Tag: T-cell redirecting therapy

Home / T-cell redirecting therapy

Categories

Talquetamab-tgvs has received accelerated approval for relapsed or refractory multiple myeloma

August 2023: Talquetamab-tgvs (Talvey, Janssen Biotech, Inc.) has been given accelerated approval by the Food and Drug Administration for the treatment of adults with relapsed or refractory multiple ...
t-cell-redirecting-therapy

Scan the code